| http://www.w3.org/ns/prov#value | - . . . .During his decade at Wyeth, Kamarck [now leading biosimilar efforts at New Merck] worked closely with etanercept (Enbrel), the $7-billion-a-year drug that Amgen and Wyeth (now Pfizer) market together to treat inflammatory diseases such as rheumatoid arthritis. ???We scanned everyone who was working on [biosimilar etanercept] to try to find the best one,??? Kamarck says. ???We felt to have o
|
